Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

Exclusion Criteria

• •Planned deceased donor liver transplantation
• •Uncontrolled / unresolved local or systemic infection
• •Body mass index \> 40
• •Planned pancreaticoduodenectomy or sleeve gastrectomy
• •Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below)
• •Pregnancy or breastfeeding
• •Non-liver cancers (we will include certain patients with primary liver cancer as detailed below)
• •Treatment with any investigational drug / device within 60 days prior to study entry
• •Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs
• •Patients who are employees or relatives of the investigator